A Scientometric Analysis of Research on the Role of NMDA Receptor in the Treatment of Depression

Overview

Journal Front Pharmacol

Date 2024 Jul 8

PMID 38974036

Authors

Xulin Chen

Xian Wang

Caijuan Li

Yao Zhang

Shanwu Feng

Shiqin Xu

Affiliations

Soon will be listed here.

Abstract

Background: There have been numerous studies on NMDA receptors as therapeutic targets for depression. However, so far, there has been no comprehensive scientometric analysis of this field. Thus, we conducted a scientometric analysis with the aim of better elucidating the research hotspots and future trends in this field.

Methods: Publications on NMDAR in Depression between 2004 and 2023 were retrieved from the Web of Science Core Collection (WoSCC) database. Then, VOSviewer, CiteSpace, Scimago Graphica, and R-bibliometrix-were used for the scientometric analysis and visualization.

Results: 5,092 qualified documents were identified to scientometric analysis. In the past 20 years, there has been an upward trend in the number of annual publications. The United States led the world in terms of international collaborations, publications, and citations. 15 main clusters were identified from the co-cited references analysis with notable modularity (Q-value = 0.7628) and silhouette scores (S-value = 0.9171). According to the keyword and co-cited references analysis, treatment-resistant depression ketamine (an NMDAR antagonist), oxidative stress, synaptic plasticity, neuroplasticity related downstream factors like brain-derived neurotrophic factor were the research hotspots in recent years.

Conclusion: As the first scientometric analysis of NMDAR in Depression, this study shed light on the development, trends, and hotspots of research about NMDAR in Depression worldwide. The application and potential mechanisms of ketamine in the treatment of major depressive disorder (MDD) are still a hot research topic at present. However, the side effects of NMDAR antagonist like ketamine have prompted research on new rapid acting antidepressants.

Citing Articles

Visual analysis of research hotspots and trends in traditional Chinese medicine for depression in the 21st century: A bibliometric study based on citespace and VOSviewer.

Song C, Chen K, Jin Y, Chen L, Huang Z Heliyon. 2025; 11(1):e39785.

PMID: 39802027 PMC: 11719390. DOI: 10.1016/j.heliyon.2024.e39785.

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity.

Comai S, De Martin S, Mattarei A, Guidetti C, Pappagallo M, Folli F Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770460 PMC: 11728621. DOI: 10.3390/ph17121618.

References

Paoletti P, Bellone C, Zhou Q . NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013; 14(6):383-400. DOI: 10.1038/nrn3504. View

Uno Y, Coyle J . Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019; 73(5):204-215. DOI: 10.1111/pcn.12823. View

Monaghan D, Irvine M, Costa B, Fang G, Jane D . Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int. 2012; 61(4):581-92. PMC: 3360989. DOI: 10.1016/j.neuint.2012.01.004. View

Shin W, Kim K, Serraz B, Cho Y, Kim D, Kang M . Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice. PLoS Biol. 2020; 18(4):e3000717. PMC: 7217483. DOI: 10.1371/journal.pbio.3000717. View

Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View

Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate Jr C, Vazquez G . Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023; 62:102127. PMC: 10430179. DOI: 10.1016/j.eclinm.2023.102127. View

Workman E, Niere F, Raab-Graham K . mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology. 2013; 73:192-203. DOI: 10.1016/j.neuropharm.2013.05.037. View

Hanson J, Yuan H, Perszyk R, Banke T, Xing H, Tsai M . Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology. 2023; 49(1):51-66. PMC: 10700609. DOI: 10.1038/s41386-023-01614-3. View

Amidfar M, Woelfer M, Reus G, Quevedo J, Walter M, Kim Y . The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 94:109668. DOI: 10.1016/j.pnpbp.2019.109668. View

10.

Nosyreva E, Szabla K, Autry A, Ryazanov A, Monteggia L, Kavalali E . Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci. 2013; 33(16):6990-7002. PMC: 3661220. DOI: 10.1523/JNEUROSCI.4998-12.2013. View

11.

BOYER P, Skolnick P, Fossom L . Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci. 1998; 10(3):219-33. DOI: 10.1007/BF02761776. View

12.

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

13.

Driver C, Jackson T, Lagopoulos J, Hermens D . Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics. Prog Neuropsychopharmacol Biol Psychiatry. 2022; 119:110609. DOI: 10.1016/j.pnpbp.2022.110609. View

14.

Hansen K, Yi F, Perszyk R, Menniti F, Traynelis S . NMDA Receptors in the Central Nervous System. Methods Mol Biol. 2017; 1677:1-80. PMC: 7325486. DOI: 10.1007/978-1-4939-7321-7_1. View

15.

Diazgranados N, Ibrahim L, Brutsche N, Newberg A, Kronstein P, Khalife S . A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67(8):793-802. PMC: 3000408. DOI: 10.1001/archgenpsychiatry.2010.90. View

16.

Hansen K, Yi F, Perszyk R, Furukawa H, Wollmuth L, Gibb A . Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018; 150(8):1081-1105. PMC: 6080888. DOI: 10.1085/jgp.201812032. View

17.

Fava M, Freeman M, Flynn M, Judge H, Hoeppner B, Cusin C . Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018; 25(7):1592-1603. PMC: 6447473. DOI: 10.1038/s41380-018-0256-5. View

18.

Krystal J, Abdallah C, Sanacora G, Charney D, Duman R . Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019; 101(5):774-778. PMC: 6560624. DOI: 10.1016/j.neuron.2019.02.005. View

19.

Phillips J, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A . Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry. 2019; 176(5):401-409. DOI: 10.1176/appi.ajp.2018.18070834. View

20.

Paul I, Nowak G, Layer R, Popik P, Skolnick P . Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 1994; 269(1):95-102. View